NCT03387904

Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma

A Randomized, Eploratory, Open Clinical Trial to Compare the Efficacy and Safety of Anlotinib Plus Irinotecan Versus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: The First Affiliated Hospital of Zhengzhou University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To compare the effects and safety of Anlotinib Plus Irinotecan versus Irinotecan in patients with esophageal squamous cell carcinoma(ESCC).

Detailed description

In recent years, anti-angiogenic therapy has made some progress in the treatment of advanced esophageal squamous cell carcinoma.In clinical use, the efficacy of antiangiogenic monotherapy was low, with a median progression-free survival (PFS) of only 3 to 4 months.We conducted a randomized, open clinical Trial to evaluate efficacy and safety of anlotinib hydrochloride combined with irinotecan versus irinotecan monotherapy in patients with advanced esophageal squamous cell carcinoma.

Conditions

• Esophageal Squamous Cell Carcinoma

Interventions

Type	Name	Description
DRUG	Anlotinib Plus Irinotecan	Anlotinib QD po.and Irinotecan Day 1,8 ivgtt.
DRUG	Irinotecan	Irinotecan Day 1,8 ivgtt

Timeline

• Start date: 2019-01-13
• Primary completion: 2021-12-01
• Completion: 2022-12-01
• First posted: 2018-01-02
• Last updated: 2021-09-02

Locations

1 site across 1 country: China